Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer

摘要

Background: Our study retrospectively assesses the safety and efficacy of the FOLFOX (oxaliplatin, fluorouracil, and leucovorin) versus DOF (docetaxel, oxaliplatin, and fluorouracil) regimens in untreated locally advanced gastric cancer (AGC). Patients and methods: A total of 108 patients underwent DOF (N=58) and FOLFOX (N=50) regimens. The end points were overall response rate (ORR), survival, and toxicity. Kaplan–Meier curve was used to estimate overall survival (OS) and progression-free survival (PFS) and Cox regression for multivariate analysis. Results: The ORRs were 50% for DOF and 30% for FOLFOX groups ( P <0.05), and disease control rates were 91.4% and 72%, respectively. The median PFS and OS in DOF group were significantly better than FOLFOX group (8.2 versus 6.4 months, P <0.05; 16.3 versus 11.2?months, P <0.001). Both groups showed acceptable toxicity; all grades and grade 3–4 toxicity had no significant differences ( P =0.071; P =0.247). However, the incidence of grade?3–4 peripheral neuropathy was significantly higher in DOF group (10.3% versus 2%, P <0.05). In the subgroup analysis for elderly AGC patients (≥65 years), administration of DOF also resulted in a superior PFS (8.5 versus 5.9 months; P =0.038) and OS (15.3 versus 9.8 months; P =0.004) compared with FOLFOX. However, DOF regimen was associated with more neutropenia (67% versus 30%; P <0.05), thrombocytopenia (61% versus 52%; P <0.05), and peripheral neuropathy (49% versus 22%; P <0.05). Conclusion: DOF regimen was more effective than FOLFOX for AGC, both in younger and older patients. The adverse effects of the two regimens were manageable. The combination of docetaxel/oxaliplatin/fluorouracil was active and well tolerated in AGC patients and deserves further evaluation. However, for elderly patients with AGC, the DOF regimen was associated with worse toxicities; therefore, the FOLFOX regimen might be a more suitable option.